Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 3
1997 1
1998 1
1999 1
2000 1
2008 1
2009 1
2010 1
2012 1
2013 2
2014 1
2015 2
2016 1
2017 1
2019 5
2020 4
2021 6
2022 2
2023 1
2024 7
2025 5
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia.
Najarian D, Sanga P, Wang S, Lim P, Singh A, Robertson MJ, Cohen K, Schotte A, Milz R, Venkatasubramanian R, T'Jollyn H, Walling DP, Galderisi S, Gopal S. Najarian D, et al. Among authors: walling dp. Int J Neuropsychopharmacol. 2022 Mar 17;25(3):238-251. doi: 10.1093/ijnp/pyab071. Int J Neuropsychopharmacol. 2022. PMID: 34791283 Free PMC article. Clinical Trial.
Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial.
Krystal JH, Kane JM, Correll CU, Walling DP, Leoni M, Duvvuri S, Patel S, Chang I, Iredale P, Frohlich L, Versavel S, Perry P, Sanchez R, Renger J. Krystal JH, et al. Among authors: walling dp. Lancet. 2022 Dec 17;400(10369):2210-2220. doi: 10.1016/S0140-6736(22)01990-0. Lancet. 2022. PMID: 36528376 Clinical Trial.
Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS, Greenwald MK, Nadipelli VR, Ling W, Heidbreder C; RB-US-13-0001 Study Investigators. Haight BR, et al. Lancet. 2019 Feb 23;393(10173):778-790. doi: 10.1016/S0140-6736(18)32259-1. Epub 2019 Feb 18. Lancet. 2019. PMID: 30792007 Clinical Trial.
Rapid Onset and Sustained Efficacy of Onfasprodil (MIJ821), a Novel NR2B Negative Allosteric Modulator, in Patients With Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study.
Shelton RC, Litman RE, Hassman H, Walling DP, Ros Montalbán S, Salvà-Coll J, Zajecka J, Sverdlov O, Gomez-Mancilla B, Healy MP, Shanker YG, Berkheimer M, Faller T, von Raison F, Serban C, Cha JH, Ghaemi SN. Shelton RC, et al. Among authors: walling dp. J Clin Psychiatry. 2025 Aug 6;86(3):23m15246. doi: 10.4088/JCP.23m15246. J Clin Psychiatry. 2025. PMID: 40767837 Clinical Trial.
Safety and Efficacy of the NMDA-2b-Selective Negative Allosteric Modulator BI 1569912: A Phase Ib Randomized Trial in Major Depressive Disorder.
McIntyre RS, Sanacora G, Walling DP, Cohen EA, Malhotra S, Rosenbrock H, Schmitz M, Scholz A, Süssmuth SD, De Crescenzo F. McIntyre RS, et al. Among authors: walling dp. Clin Pharmacol Ther. 2025 Nov;118(5):1202-1212. doi: 10.1002/cpt.70018. Epub 2025 Aug 14. Clin Pharmacol Ther. 2025. PMID: 40810366 Free PMC article. Clinical Trial.
46 results